triple acting glp 1 Schematic illustration of monoagonists, dual agonists and glp 1 signaling GLP-1-based therapies

After a dose-titration and dose-stable run-in period of up to 16 weeks and a 2-week placebo run-in period, patients with inadequate glycemic control (A1C 7.5% to 10.5%) were randomized to the addition of either 100 mg of JANUVIA or placebo, administered once daily

Participants were randomized to receive once-daily liraglutide (1.8 mg) after a 2-week titration time or insulin glargine85)

Using the Wegovy Pen

This waiting period typically ranges from 30 to 90 days depending on the specific center's medical director guidance

Waiting 4 weeks between dose escalations allows the body to adapt to increasing drug exposure and minimizes gastrointestinal adverse effects, the most common reason for treatment discontinuation

People currently on GLP-1 medications who want gut support